Merck Sharp + Dohme Corp.

Indiana University

Ambrx, Inc.

Msd Italia S.r.l.

Ambryx, Inc.

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.r.l.

Paul E Carrington

Elisabetta Bianchi

Antonello Pessi

Federica Orvieto

Anandan Palani

Ravi P Nargund

Qiaolin Deng

Nick Knudsen

Tomi K Sawyer

Robert M Garbaccio

Wolfgang Seghezzi

Dennis P Gately

Anthony Manibusan

Grigori Ermakov

Richard Dennis DiMarchi

Thomas Joseph Tucker

Armin Lahm

Alessia Santoprete

Chengwei Wu

Joseph M Metzger

Brian P Ward

Paolo Ingallinella

Donald J Marsh

Ranabir Sinha Roy

George J Eiermann

Elena Capito

Alessandro Pocai

Anna Demartis

Richard Dimarchi

Described are antibody peptide conjugates (APCs) comprising an antibody conjugated to a peptide analog of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have agonist activity at the glucagon (GCG) receptor and the glucagon-like peptide 1 (GLP-1) receptor and the use of such APCs for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.

Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors

Long-acting co-agonists of the glucagon and GLP-1 receptors are described.

Long-acting co-agonists of the glucagon and GLP-1 receptors

Co-agonists of the glucagon and GLP-1 receptors are described.

Co-agonists of the glucagon and GLP-1 receptors

Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (GLP-1) receptor and the glucagon (GCG) receptor, and the use of such GLP-1 receptor/GCG receptor co-agonists for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.

Peptide analogs of oxyntomodulin (OXM, glucagon-37), which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to act as a dual GLP-1/glucagon receptor (GCGR) agonist are described. The peptide analogs are useful for treatment of metabolic disorders such as diabetes and obesity.

Oxyntomodulin analogs

Growing community of inventors

South San Francisco, CA, United States of America

Paul E Carrington